Menu Search
Equities

MicroTech Medical Hangzhou Co Ltd

2235:HKG.HS

MicroTech Medical Hangzhou Co Ltd

Actions
  • Price (HKD)4.07
  • Today's Change-0.01 / -0.25%
  • Shares traded116.90k
  • 1 Year change-40.84%
  • Beta--
Data delayed at least 15 minutes, as of May 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MicroTech Medical Hangzhou Co Ltd is a China-based company that mainly engaged in research, production and commercialization of diabetes treatment and diabetes monitoring. The Company's products such as applicator insulin pump system (Equil), blood glucose monitoring system and continuous blood glucose monitoring system (AiDEX G7) have been commercialized. The Company's products, such as artificial pancreas, are in the process of research and development. The Company's products are sold to overseas markets such as the United States and the European Union.

  • Revenue in HKD (TTM)230.53m
  • Net income in HKD-49.64m
  • Incorporated2011
  • Employees760.00
  • Location
    MicroTech Medical Hangzhou Co LtdNo. 108 Liuze StreetCangqian Street, Yuhang DistrictHANGZHOU ChinaCHN
  • Websitehttps://www.microtechmd.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.